A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma
Phase of Trial: Phase III
Latest Information Update: 17 Sep 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Neovascular glaucoma
- Focus Registrational; Therapeutic Use
- Acronyms VEGA
- Sponsors Bayer
- 09 Sep 2016 Status changed from active, no longer recruiting to completed.
- 29 Jun 2016 Status changed from recruiting to active, no longer recruiting.
- 23 May 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016.